- Home
- RDHL vs CERO Comparison
RDHL vs CERO Comparison
Compare RDHL & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- CERO
- Stock Information
- Founded
- RDHL 2009
- CERO 2017
- Country
- RDHL Israel
- CERO United States
- Employees
- RDHL N/A
- CERO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- RDHL Health Care
- CERO
- Exchange
- RDHL Nasdaq
- CERO Nasdaq
- Market Cap
- RDHL 7.5M
- CERO 8.4M
- IPO Year
- RDHL N/A
- CERO N/A
- Fundamental
- Price
- RDHL $5.64
- CERO $2.34
- Analyst Decision
- RDHL
- CERO
- Analyst Count
- RDHL 0
- CERO 0
- Target Price
- RDHL N/A
- CERO N/A
- AVG Volume (30 Days)
- RDHL 13.8K
- CERO 80.5M
- Earning Date
- RDHL 08-29-2024
- CERO 02-20-2025
- Dividend Yield
- RDHL N/A
- CERO N/A
- EPS Growth
- RDHL N/A
- CERO N/A
- EPS
- RDHL N/A
- CERO N/A
- Revenue
- RDHL $3,707,000.00
- CERO N/A
- Revenue This Year
- RDHL $224.90
- CERO N/A
- Revenue Next Year
- RDHL $82.69
- CERO N/A
- P/E Ratio
- RDHL N/A
- CERO N/A
- Revenue Growth
- RDHL N/A
- CERO N/A
- 52 Week Low
- RDHL $5.41
- CERO $2.22
- 52 Week High
- RDHL $31.50
- CERO $1,280.00
- Technical
- Relative Strength Index (RSI)
- RDHL 35.38
- CERO 32.54
- Support Level
- RDHL $5.41
- CERO $2.83
- Resistance Level
- RDHL $5.79
- CERO $3.50
- Average True Range (ATR)
- RDHL 0.31
- CERO 1.13
- MACD
- RDHL -0.05
- CERO 0.05
- Stochastic Oscillator
- RDHL 14.26
- CERO 1.43
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.